Evidence map›Paper›PMID 41991901›Full record

Trial reportHIV medicine2026

Longitudinal changes in plasma biomarkers of immune activation, neuronal inflammation and injury in persons with HIV initiating ART.

Merle Henderson, Peter Dutey-Magni, Carolina Herrera, Wolfgang Stöhr, Alejandro Arenas-Pinto, Owen Swann, Amanda Heslegrave, Henrik Zetterberg, John Tregoning, Sarah Fidler and 4 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in HIV medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Merle HendersonDepartment of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK.ORCID https://orcid.org/0000-0003-3326-9674
Peter Dutey-MagniMRC Clinical Trials Unit, University College London, London, UK.
Carolina HerreraCONRAD, Macon & Joan Brock Virginia Health Sciences at Old Dominion University, Norfolk, Virginia, USA.
Wolfgang StöhrMRC Clinical Trials Unit, University College London, London, UK.
Alejandro Arenas-PintoMRC Clinical Trials Unit, University College London, London, UK.
Owen SwannUK Dementia Research Institute, University College London, London, UK.
Amanda HeslegraveUK Dementia Research Institute, University College London, London, UK.
Henrik ZetterbergUK Dementia Research Institute, University College London, London, UK.
John TregoningDepartment of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK.
Sarah FidlerDepartment of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK.ORCID https://orcid.org/0000-0003-1676-7583
François RaffiCentre Hospitalier Universitaire, Nantes, France.
Andrea CalcagnoDepartment of Infectious Disease, University of Turin, Turin, Italy.ORCID https://orcid.org/0000-0003-2534-8815
Ab BabikerMRC Clinical Trials Unit, University College London, London, UK.
Alan WinstonDepartment of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK.

Funding

European Union LSHP-CT-2006-037570Gilead SciencesJanssen PharmaceuticalsMerck LaboratoriesNational Institute for Health and Care Research University College London Hospitals Biomedical Research CentreNEAT-IDThe French National Institute of Health and Medical ResearchUK Dementia Research Institute UKDRI-1003
6 · The paper itself

Abstract

backgroundData on changes in biomarkers of brain health, and their associations with cognitive function in adults commencing either dual- or triple-antiretroviral therapy (ART) are sparse.

methodsPlasma biomarkers (neurofilament light [NfL], glial fibrillary acidic protein [GFAP], sCD14, CXCL10, neopterin and IL-6) were measured at baseline and after 96 weeks on ART in individuals randomized to darunavir/ritonavir and either tenofovir-DF/emtricitabine (triple-ART, n = 119) or raltegravir (dual-ART, n = 119) in NEAT-001/ANRS143. Regression models examined associations of baseline and week-96 biomarker concentrations with HIV clinical parameters, composite cognitive test scores (Standardized neuropsychological test [NPZ], 7-domains) and treatment arm.

resultsIn 238 individuals, median age was 38 (interquartile range [IQR] 31, 46) years, 87% male and 83% of white ethnicity. Baseline median log

conclusionsPlasma biomarkers of brain health improved following ART initiation, associated predominantly with improvements in CD4 count and partly with treatment arm.

Indexed as

Anti-HIV AgentsAnti-Retroviral AgentsBiomarkersHIV InfectionsAdultAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountChemokine CXCL10FemaleGlial Fibrillary Acidic ProteinHumansInflammationInterleukin-6Lipopolysaccharide ReceptorsLongitudinal StudiesMaleAnti-HIV AgentsAnti-Retroviral AgentsBiomarkersChemokine CXCL10CXCL10 protein, humanGFAP protein, humanGlial Fibrillary Acidic ProteinInterleukin-6Lipopolysaccharide ReceptorsNeopterinneurofilament protein LNeurofilament Proteinsantiretroviral therapybiomarkerscentral nervous systemcognitive functionneuroinflammation

Identifiers

PMID41991901
PMCPMC13340942

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.